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Abstract In the small intestine of celiac disease patients,
dietary wheat gluten and similar proteins in barley and rye
trigger an inflammatory response. While strict adherence to
a gluten-free diet induces full recovery in most patients, a
small percentage of patients fail to recover. In a subset of
these refractory celiac disease patients, an (aberrant)
oligoclonal intraepithelial lymphocyte population develops
into overt lymphoma. Celiac disease is strongly associated
with HLA-DQ2 and/or HLA-DQ8, as both genotypes
predispose for disease development. This association can
be explained by the fact that gluten peptides can be
presented in HLA-DQ2 and HLA-DQ8 molecules on
antigen presenting cells. Gluten-specific CD4
+ T cells in
the lamina propria respond to these peptides, and this likely
enhances cytotoxicity of intraepithelial lymphocytes against
the intestinal epithelium. We propose a threshold model for
the development of celiac disease, in which the efficiency
of gluten presentation to CD4
+ T cells determines the
likelihood of developing celiac disease and its complica-
tions. Key factors that influence the efficiency of gluten
presentation include: (1) the level of gluten intake, (2) the
enzyme tissue transglutaminase 2 which modifies gluten
into high affinity binding peptides for HLA-DQ2 and HLA-
DQ8, (3) the HLA-DQ type, as HLA-DQ2 binds a wider
range of gluten peptides than HLA-DQ8, (4) the gene dose
of HLA-DQ2 and HLA-DQ8, and finally,(5) additional
genetic polymorphisms that may influence T cell reactivity.
This threshold model might also help to understand the
development of refractory celiac disease and lymphoma.
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With a prevalence of 1% in western populations, celiac disease
(CD)is one of the most commoninflammatorydisordersof the
small intestine (GreenandCellier 2007). CD is often assumed
to have its onset in childhood, but it has recently been
suggested that adults can also develop CD (Vilppula et al.
2009). Clinical manifestations vary according to age group:
infants and young children present with diarrhea, abdominal
distention, and failure to thrive, whereas adults that develop
CD not only present with diarrhea, but also with silent
manifestations such as anemia, osteoporosis, or neurological
symptoms (Green and Cellier 2007). Immunohistochemistry
of the small intestine of patients shows villous atrophy, crypt
hyperplasia, and elevated levels of intraepithelial lymphocytes
(IELs). The only therapy until now is a gluten-free diet,
which will normalize the clinical and histological manifes-
tations and allows the patients to live an otherwise normal
life.
A small percentage of adult-onset CD patients develop a
primary or secondary resistance to a gluten-free diet (Fig. 1).
This condition is called refractory celiac disease (RCD) and is
characterized by persisting villous atrophy and elevated levels
of IELs. Currently, RCD is subdivided into two subtypes:
RCD type I (RCD I) and RCD type II (RCD II) that both
display clinical and histological resistance to a gluten-free diet
(Daum et al. 2005). RCD II, however, is associated with the
presence of an aberrant IEL population that lacks surface T
cell receptor (TCR)-CD3 expression, but contains intracellu-
lar CD3ε and has clonal TCRγ-gene rearrangements (Cellier
et al. 1998). These aberrant IELs can gain chromosomal
abnormalities and develop into surface TCR-CD3
- lymphoma
cells (Deleeuw et al. 2007;V e r k a r r ee ta l .2003). RCD II is
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50% of the RCD II patients develop overt lymphoma within
5 years of diagnosis (Al-Toma et al. 2007; Malamut et al.
2009). In summary, the majority of CD patients has an
uncomplicated disease course and can be treated with a
gluten-free diet (Fig. 1). RCD II and RCD-associated
lymphoma, however, are difficult to treat and have therefore
poor 5-year survival rates of <44% and <20%, respectively
(Al-Toma et al. 2007).
The development of CD is determined by both environ-
mental and genetic factors. In the 1950s, ingestion of wheat
products was described to cause malabsorption symptoms in
patients (Dicke et al. 1953). Later on, it was established that
gluten, the storage proteins in wheat, barley and rye, caused
a cell-mediated immune response in the small intestine
(Ferguson et al. 1975). In addition to this environmental
factor, CD development involves genetic predisposition, as
the vast majority of the CD patients possess human
leukocyte antigen (HLA)-DQ2 and/or HLA-DQ8 (Spurkland
et al. 1997). HLA-DQ2 is a genotype that is present in
roughly 25% of the European population (Bourgey et al.
2007; Fig. 1). Yet, only ~4% of all HLA-DQ2
+ individuals
develop CD (Fig. 1)( W o l t e r sa n dW i j m e n g a2008). CD
development in HLA-DQ2- and HLA-DQ8-negative indi-
viduals is extremely rare (Karell et al. 2003). These findings
came together with the observation that CD4
+ Tc e l ll i n e s
from duodenal biopsies of CD patients specifically respond
to gluten peptides presented by HLA-DQ2 and/or HLA-DQ8
(Lundin et al. 1993, 1994). The etiology of RCD is much
less clear, but seems to be associated with HLA-DQ2
(Al-Toma et al. 2006).
In short, the complex interplay of multiple genetic and
environmental factors will determine the development of
CD and its complications. This review describes current
knowledge on gluten, HLA-DQ, and the immunopatho-
genesis of CD and its complications. In addition, we
present a likely sequence of events in the development of
CD and discuss the factors that may influence the risk of
CD development.
Gluten: the disease-inducing environmental trigger
The visco-elastic properties of gluten are essential for
dough formation of wheat flour and give bread its unique
texture and taste. Because of its unique properties, gluten is
widely used in the food industry: not only in products that
are readily associated with wheat, like bread, cookies and
pasta, but also as a hidden ingredient in sauces, instant
soups, and even medication. Consequently, the daily gluten
intake on a gluten-containing diet in Western Europe and
the United States is high, between 15 and 20 g per day. The
omnipresence of gluten makes adherence to a gluten-free
diet challenging for CD patients.
Gluten is a heterogeneous mixture of gliadins and
glutenins in wheat or similar proteins in barley and rye.
Each wheat variety expresses multiple α-, γ-, and
ω-gliadins in addition to low- and high-molecular weight
glutenins. Gluten has a very high content of the amino acids
glutamine (30%) and proline (15%). By virtue of its high
glutamine content, gluten is rich in nitrogen, an essential
factor for seed germination. The high proline content
renders gluten highly resistant to degradation by gastroin-
testinal enzymes, making it possible for large immunogenic
gluten peptides to reach the mucosal surface (Shan et al.
2002, 2005). As modern wheat varieties contain three
complete genomes encoding gliadins and glutenins, up to
100 different gluten proteins may be present in a single
wheat variety, and many of these are implicated in the
pathogenesis of CD.
HLA-DQ: the strongest disease-associated
gene locus by far
The strong genetic influence in CD is apparent, as the
concordance between monozygotic twins is 80%, whereas in
dizygotic twins, this is only 11% (Nistico et al. 2006), which
is approximately the same as the risk for first-degree relatives
(Dube et al. 2005). The main genetic influence in CD is
Fig. 1 Prevalence of CD and complicated CD in the Caucasian
population. Approximately 25% of the general Caucasian population
is HLA-DQ2
+. From these genetically susceptible individuals, only
4% develop CD. In majority of the CD patients, the disease course is
uncomplicated. Roughly 3% of the CD patients will not respond to a
gluten-free diet and develop RCD. A subset of RCD patients develop
RCD II of which approximately 50% develop RCD-associated
lymphoma (not shown)
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predominance of HLA-B8 and HLA-DR3 serotypes in CD
patients (Falchuk et al. 1972; Keuning et al. 1976). Later
studies established that the strongest association is with
HLA-DQ2 (DQA*0501, DQB*0201, termed HLA-DQ2.5
hereafter) (Sollid et al. 1989), which is encoded together with
HLA-B8 and HLA-DR3 on the highly conserved ancestral
haplotype 8.1 (Price et al. 1999). CD is associated, to a lesser
extent, with HLA-DQ8 (DQA*03, DQB*0302) (Spurkland
et al. 1997). The strong association between HLA-DQ2.5
and CD is further illustrated by the observation that
individuals homozygous for HLA-DQ2.5 have a fivefold
increased risk for development of CD compared to individ-
uals heterozygous for HLA-DQ2.5 (Mearin et al. 1983).
Similarly, HLA-DQ 2.5 homozygosity is associated with the
development of RCD II and RCD-associated lymphoma,
whereas this association is less clear for HLA-DQ2.5
heterozygosityandHLA-DQ8(Al-Tomaetal.2006). Another
HLA-DQ2 variant exists: HLA-DQ2.2 (DQA*0201,
DQB*0202), which has a peptide-binding motif that
is almost identical to that of HLA-DQ2.5 (van de Wal
et al. 1997). Whereas HLA-DQ2.5 predisposes to CD,
HLA-DQ2.2 does not. This difference is related to the
peptide-binding properties of these HLA-DQ2 variants (see
below). The estimated risk effect of HLA-DQ2 and HLA-
DQ8 on CD development is estimated to be ~35% (Hunt
et al. 2008).
Not all HLA-DQ2.5
+ and HLA-DQ8
+ individuals
develop CD, indicating that these HLA genotypes are
necessary, but not sufficient for CD development. Recent
large-scale genetic association studies identified many
additional genetic loci that all make a small contribution
to the risk to develop CD (Box 1 and Table 1). Importantly,
most of these genes encode proteins involved in immunity,
which supports the notion that CD is an immune-related
disorder and possibly provides clues on the immunopatho-
genesis of CD.
The adaptive immune response: gluten, HLA-DQ,
and CD4
+ T cells
As noted above, CD develops almost exclusively in HLA-
DQ2.5
+ or HLA-DQ8
+ individuals. It is also well estab-
lished that in CD patients, gluten-derived peptides
presented by either HLA-DQ2.5 or HLA-DQ8 induce a
CD4
+ T cell response. Both HLA-DQ2.5 and HLA-DQ8
prefer to bind peptides with negatively charged amino acids
at anchor residues. Gluten peptides, however, are virtually
devoid of negative charges, and native gluten peptides thus
bind poorly to HLA-DQ2.5 or HLA-DQ8. Consequently,
CD4
+ T cells specific for native gluten peptides are rare. It
has become clear that the enzyme tissue transglutaminase 2
(TG2) can modify gluten peptides to fit the requirements
for high affinity binding to HLA-DQ2 and HLA-DQ8
(Molberg et al. 1998; van de Wal et al. 1998a). TG2 can
convert non-charged glutamine into negatively charged
glutamic acid, a process called deamidation. Because gluten
has a high content of glutamine (Q) and proline (P), the
sequences QP, QXP and QXXP (in which X can represent
any amino acid) are frequently found in gluten peptides.
Strikingly, only in the sequence QXP that the glutamine is
converted, which results in highly selective introduction of
negative charges in gluten peptides (Vader et al. 2002). This
specific deamidation process introduces the negative
charges at the positions favored by HLA-DQ2 and HLA-
DQ8, thereby expanding the presentable gluten peptide
repertoire (Fig. 2). As a result, the gluten-specific CD4
+ T
cell repertoire is substantially expanded, which enhances
the inflammation and disease development (Fig. 2).
TG2 is mostly retained intracellularly in an inactive form
and is activated upon its release during tissue damage
(Lorand and Graham 2003; Siegel et al. 2008). Therefore,
something should trigger tissue damage which initiates
TG2 release, allowing the modification of gluten peptides.
Whereas CD4
+ T cell responses against native gluten
Box 1 Non-HLA genes associated with CD
Candidate gene association study: Candidate genes, selected on the basis of current understanding of CD immunopathology, were tested for
association with CD. Genes studied with this approach include, among others, IFN-γ, FAS, TCR, and TG2 (van Heel et al. 2005). No
convincing association with CD was found.
Genetic linkage study: This approach is aimed at the identification of chromosomal regions that likely contain disease-causing genes in families
with a high prevalence of CD. The genomic region 2q33 showed linkage to celiac disease in multiple populations. This region contains the
genes CD28, CTLA4, and ICOS which all control different aspects of the T cell response (van Heel et al. 2005). Linkage was also found for
chromosome 5q31-33 (Greco et al. 2001) and chromosome 19p13.1 (van Belzen et al. 2003). Linkage to these regions, however, could not
always be replicated in other populations.
Genome-wide association study: In recent years, it has become possible to perform large-scale case control-based association studies using single
nucleotide polymorphisms. With this approach, it is possible to identify common variants in the genome that predispose to disease. Until now,
ten non-HLA loci associated with CD have been identified and linkage to 2q33 has been confirmed (Table 1) (Hunt et al. 2008;Trynka et al.
2009;van Heel et al. 2007). Recently, 13 additional true risk variants and 13 suggestive risk variants were identified (Dubois et al. 2010).
Although causality has only been proven for the risk allele SH2B3 (Zhernakova et al. 2010), it is clear that nearly all associated regions contain
genes involved in immune response.
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breach in oral tolerance to gluten. The presentation of
native gluten peptides by HLA-DQ2 or HLA-DQ8 to CD4
+
T cells will lead to the production of IFN-γ (Fig. 2). IFN-γ
will in turn lead to higher expression of the HLA-DQ
molecules and thereby, to increased gluten peptide presen-
tation (Fig. 2). In the presence of gluten, this could become
a self-amplifying loop that could cause limited tissue
damage locally. This tissue damage would lead to the
release of TG2 that will modify native gluten peptides into
high affinity ligands for HLA-DQ2 and/or HLA-DQ8,
thereby expanding the gluten-specific CD4
+ T cell
responses and leading to additional tissue damage: the
initiation of a second self-amplifying loop (Fig. 2). Alter-
natively, infections occurring in the gastrointestinal tract
would generate a pro-inflammatory milieu that might lead
to loss of tolerance to native gluten peptides and generate
tissue damage simultaneously and thus, initiate deamidation
by TG2.
Activated intraepithelial lymphocytes damage
the intestinal epithelium
Intraepithelial lymphocytes are localized between intestinal
epithelial cells at the basolateral side of the epithelium and
are thought to play an important role in immunosurveil-
lance of the epithelium. The IEL population in the small
intestine is a mixed population of TCRαβ
+ Tc e l l s ,
TCRγδ
+ T cells, and NK cells, although the vast majority
Table 1 Loci associated with CD development
Locus Gene candidate Function Odds ratio
a
6p21 HLA Antigen presentation 6.23 (5.95–6.52)
3q25-3q26 IL12A Subunit of IL12, regulates Th1 differentation 1.36 (1.29–1.44)
3p21 CCR1, CCR2, CCR3 and CCR5 Recruitment of immune cells to the site of inflammation 1.30 (1.23–1.39)
3q28 LPP Possible role in maintaining cell shape 1.29 (1.25–1.34)
6q23 TNFAIP3 Inhibits NFκB activation and TNF-mediated apoptosis 1.23 (1.17–1.28)
12q24 SH2B3 Adaptor molecule involved in signaling in T cells 1.20 (1.15–1.24)
2q11-2q12 IL18R1 and IL18RAP Respectively the α and β-chain of IL18 receptor,
IL18 is a pro-inflammatory cytokine
1.19 (1.14–1.25)
6q25 TAGAP Role in modulating cytoskeletal changes 1.16 (1.12–1.21)
2p16 REL Component of NFκB transcription complex 1.15 (1.11–1.20)
2q33 CTLA4 Inhibitory effect on the T cell response 1.14 (109–1019)
CD28 Stimulating effect on the T cell response
ICOS Stimulating effect on the T cell response
1q31 RGS1 Acts as GTPase activating protein, thereby
regulating cell signating
0.80 (0.76–0.84)
4q27 IL2 Stimulating proliferation of T cells 0.74 (0.70–0.78)
IL21 Regulates the function of T and NK cells
aOdds ratios from (Dubois et al. 2010)
Fig. 2 Self-amplifying loops in the development of CD. HLA-DQ2
+
or HLADQ8
+ individuals can present native gluten peptides on their
APC to CD4
+ T cells. The IFN-γ released in this process can in turn
boost HLA-DQ2/8 expression. This low-grade inflammation might
eventually lead to tissue damage with TG2 release. TG2 is able to
expand the presentable gluten peptide repertoire by deamidation. As a
result, the CD4
+ T cell response is strongly enhanced, leading to more
IFN-γ, tissue damage, and increased release of TG2. The end result is
full-blown CD
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+ TCRαβ
+ T cells (Jabri and Ebert
2007). Furthermore, most of these TCR
+ IELs express a
variety of NK cell receptors that is distinct from the NK cell
receptors expressed on blood T cells (Jabri et al. 2000). The
NK cell receptors are thought to act mainly as T cell co-
stimulators, lowering the threshold for T cell activation in
stressful times (Bauer et al. 1999).
In active CD, the number of CD8
+ TCRαβ
+ and
TCRγδ
+ IELs is markedly increased. It is unclear whether
this is a response to changes in the homeostasis of the
epithelium, or a consequence of the pro-inflammatory
milieu created by the CD4
+ T cell response in the lamina
propria (Fig. 3). Similar to IELs of normal controls, IELs
from active CD express NK cell receptors. When compared
to normal controls, however, IELs from CD patients have
acquired a more activating NK cell receptor repertoire
(Jabri et al. 2000). In the healthy small intestine, IELs
predominantly express the inhibitory CD94/NKG2A recep-
tor. In contrast, IELs in CD express high levels of activating
receptors like CD94/NKG2C and NKG2D (Meresse et al.
2004, 2006). Simultaneously, intestinal epithelial cells in
CD upregulate MIC and HLA-E, the ligands for NKG2D
and CD94/NKG2C, respectively. Interaction of NKG2D
and CD94/NKG2C with their ligands will enhance IFN-γ
production and cytolysis, leading to tissue damage (Fig. 3).
An important factor in acquiring an activating NK cell
receptor repertoire is interleukin 15 (IL-15; Box 2), which
has been shown to upregulate both NKG2D and CD94/
NKG2C on IELs of active CD patients and boost their
ability to lyse enterocytes (Meresse et al. 2004, 2006). In
addition, IL-15 can alter the NK cell receptor function,
leading to NK cell receptor-mediated cytotoxicity indepen-
dent of TCR specificity (Meresse et al. 2004, 2006). In
conclusion, while gluten-specific CD4
+ T cells elicit an
inflammatory response in the lamina propria, IELs in the
epithelium acquire activating NK receptors and the ability
to lyse stressed epithelial cells independent of T cell
receptor signaling, which likely contributes to the typical
tissue damage in CD.
In RCD, the survival, expansion, and acquisition of an
NK cell-like phenotype by IELs is even more pronounced
than in CD, possibly as a result of the presence of larger
amounts of IL-15. RCD II patients have an aberrant clonal
IEL population that lacks surface TCR-CD3 expression.
Studies on aberrant TCR-CD3
- IEL lines from RCD II
patients showed that, upon stimulation with IL-15, these
cell lines express granzyme B and lyse the intestinal
epithelial cell line HT29, suggesting a role for aberrant
IELs in perpetuating epithelial damage in RCD II (Mention
et al. 2003). Therefore, IL-15-dependent NK cell-like
transformation of IELs may be an essential step in the
immunopathology of RCD.
A threshold model for the risk of CD development
The expansion of the presentable gluten peptide repertoire
due to the release and activity of TG2 is a critical step in the
pathogenesis of full-blown CD. Several lines of evidence
support the notion that the level of gluten presentation to T
cells critically influences the risk of disease development.
First, HLA-DQ2.5 homozygous individuals have a
fivefold higher risk of CD development than HLA-DQ2.5
heterozygous individuals (Mearin et al. 1983). This gene
dose effect directly correlates with the magnitude of the
CD4
+ T cell response: antigen presenting cells (APC) from
HLA-DQ2.5 homozygous individuals induce very strong
proliferative T cell responses and IFN-γ production, while
APC from HLA-DQ2.5/DQX heterozygous individuals
Fig. 3 Crosstalk between the CD4
+ Tcell response and IEL
cytotoxicity. The CD4
+ T cell response to gluten may lead to IFN-γ
production and potentially to upregulation of IL-15, which in turn
boosts IEL-mediated cytotoxicity. Activated IELs lyse the epithelium,
which leads to TG2 release and subsequent deamidation of gluten
peptides. This may constitute yet another self-amplifying feedback
loop, as deamidation of gluten peptides will enhance the CD4
+ T cell
response (see Fig. 2)
Box 2 IL-15
IL-15 is a cytokine that, just as IL-2, is able to induce T cell
proliferation, IFN-γ production, and cytotoxicity. Furthermore, IL-
15 is known to play an important role in NK cell development and
activation (Fehniger and Caligiuri 2001). Under normal circum-
stances, IL-15 expression is strictly regulated at the level of
transcription, translation, and secretion (Budagian et al. 2006). In
CD, this regulation is disrupted, which results in massive
upregulation of IL-15 in the epithelium and lamina propria. The
abnormal availability of IL-15 results in chronic inflammation by
survival, proliferation, and activation of IELs (Di Sabatino et al.
2006;Ebert 1998). Furthermore, IL-15 can exert an inhibitory effect
on TGF-β, a negative regulator of the immune response (Benahmed
et al. 2007). Recently, it has been shown that IL-15 can synergize
with IL-21, a cytokine expressed on CD4
+ T cells and a stimulator
of IFN-γ production and cytolytic activity of CD8
+ T cells and NK
cells (Ebert 2009;Parrish-Novak et al. 2000).
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data indicate that the number of HLA-DQ2.5 molecules
capable of presenting gluten peptides on the surface of APC
will define the magnitude of the CD4
+ T cell response.
Second, whereas HLA-DQ2.5 is associated with CD
development, the homologous HLA-DQ2.2 is not. Al-
though these two variants have almost identical peptide-
binding motifs, HLA-DQ2.2 can only bind a subset of the
gluten peptides that can bind to HLA-DQ2.5. This
difference is explained by the fact that a proline at position
3 in peptides has an adverse effect on peptide binding to
HLA-DQ2.2 (van de Wal et al. 1997). As gluten epitopes
cluster in proline-rich regions (Arentz-Hansen et al. 2002),
many gluten peptides have a proline at position 3 and do
not bind to HLA-DQ2.2 (Vader et al. 2003b). Consequently,
HLA-DQ2.5 is able to present a much broader repertoire of
gluten peptides than HLA-DQ2.2. In addition, HLA-DQ2.5
is better at retaining gluten peptides in its binding groove
compared to HLA-DQ2.2 (Fallang et al. 2009). As a result,
gluten peptide presentation by HLA-DQ2.5 is protracted
compared to presentation by HLA-DQ2.2, which will
increase the chance for productive CD4
+ Tc e l ls t i m u l a t i o n .
Third, CD is associated mainly with HLA-DQ2.5 and, to
a lesser extent, with HLA-DQ8. Although a variety of
gluten peptides has been identified that can stimulate HLA-
DQ8 restricted T cells from CD patients, one α-gliadin
peptide in particular appears to be immunodominant, as this
peptide invariably induces specific T cell responses in
HLA-DQ8
+ CD patients (Henderson et al. 2007; Tollefsen
et al. 2006; van de Wal et al. 1998b, 1999; Kooy et al.
unpublished data). In contrast to the HLA-DQ2.5 restricted
α-gliadin peptides, the HLA-DQ8 peptide is not derived
from a proline-rich region of the α-gliadin protein, and
therefore likely susceptible to degradation in the gastroin-
testinal tract. Furthermore, whereas for HLA-DQ2 a single
deamidation in a gluten peptide is sufficient to evoke a
CD4
+ T cell response, for HLA-DQ8, deamidation at two
positions is preferred (Henderson et al. 2007), which may
limit the generation of strong antigenic gluten peptides. The
fact that the immunodominant HLA-DQ8 peptide is more
readily degraded and requires more deamidation steps,
limits the availability for antigen presentation and may
therefore limit the risk to develop CD.
Fourth, further evidence that the level of gluten
presentation is a critical parameter comes from a totally
different angle: most CD patients tolerate oat even though it
has been shown that the gluten-like molecules in oat can
elicit CD4
+ T cell responses in CD patients (Arentz-Hansen
et al. 2004; Vader et al. 2003a) There are two striking
differences between the relatively safe oat and the disease-
inducing cereals wheat, barley, and rye: (1) while the
gluten-like molecules in oat contain only two antigenic
sequences, dozens are found in gluten and the gluten-like
molecules of barley and rye, (2) the “gluten” content of oat
is much lower compared to the other cereals. Consumption
of oat thus results in a much lower exposure to antigenic
peptides, in comparison with the other cereals, and this is
apparently tolerated, as it does not lead to disease in the
majority of patients.
Collectively, these data indicate the presence of a
threshold to develop CD. Initiation of CD becomes more
likely with increased T cell exposure to gluten antigens.
This exposure is influenced by the type and amount of
HLA-DQ, as this determines the efficiency of gluten
peptide presentation to CD4
+ T cells. For HLA-DQ2.5
homozygous individuals, the threshold to develop CD is
most easily exceeded, whereas for HLA-DQ2.2
+ and HLA-
DQ8
+ individuals, the threshold is much higher.
CD development: a series of unfortunate events
The past two decades have witnessed the identification of
several critical immunological factors in CD, from which a
likely sequence of events in the development of this disease
can be deduced. It is well known that healthy individuals
can have antibodies against native gluten peptides. As an
antibody response is controlled by CD4
+ T cell help, such
individuals most likely have CD4
+ T cells specific for
native gluten peptides, indicating that the mere presence of
such T cells is, in general, not sufficient to exceed the
threshold to develop CD (Fig. 4). This indicates that in the
majority of individuals, tolerogenic and regulatory process-
es in the intestine keep gluten-specific T cell responses in
check. This steady state can be breached by frequent
episodes of enteroviral infections, as this leads to the
secretion of inflammatory cytokines and differentiation of
Th1 cells (Stene et al. 2006), thereby enhancing the
response to gluten (Fig. 4). Subsequently, the combined
effect of low-level gluten reactivity and pathogen-
induced inflammation could lead to tissue damage and
the release of TG2. In turn, the activity of TG2 would
generate a large repertoire of deamidated gluten peptides
with high affinity for HLA-DQ, thereby boosting the
gluten-specific T cell response (Fig. 4). At this point in
CD development, self-amplifying loops are in action:
CD4
+ T cell responses against native gluten peptides lead
to IFN-γ production to upregulation of HLA, and further
amplification of the gluten-specific T cell response. TG2
released upon tissue damage expands the presentable
gluten peptide repertoire, which will ultimately lead to
more tissue damage (Fig. 2). Due to the massive
expansion of the gluten-specific T cell pool, regulatory
processes are no longer able to contain the T cell
responses, and exposure to gluten suffices to perpetuate
inflammation. Eliminating gluten from the diet is the only
646 Immunogenetics (2010) 62:641–651way to stop this process. At all stages in this scenario, the
risk to develop CD is influenced by the HLA-DQ
genotype, as HLA-DQ2.5 homozygous individuals will
present more HLA-gluten complexes than HLA-DQ2.5
heterozygous individuals (Fig. 4). Simultaneously, an
infiltrate of IELs is formed in the epithelium, which is
potentially driven by the inflammatory milieu created by
CD4
+ T cells in the lamina propria. These IELs upregulate
activating NK cell receptors and acquire the ability to lyse
enterocytes independent of the TCR.
The development of full-blown CD is most likely the
result of an unfortunate series of events which, in isolation,
would not lead to disease, but, combined, have a detrimen-
tal outcome. It is important to note that exposure to gluten,
frequent enteroviral infections, and occasional TG2 activa-
tion likely occur in every individual, but usually do not
result in CD development, even in HLA-DQ2
+ and/or
HLA-DQ8
+ individuals (Fig. 1). It has now become clear
that the presence of a higher number of additional non-
HLA risk alleles (Table 1) is directly correlated with an
increase in the risk to develop CD (Romanos et al. 2009).
This suggests that the influence of non-HLA genes lowers
the threshold to develop CD and could skew the balance
towards disease development (Fig. 4). It is plausible that
non-HLA genes also increase the risk to develop compli-
cated CD, although this hypothesis will be difficult to test
as this patient population is very small. Thus, even though
key pieces of the celiac puzzle have been collected and
assembled, the picture is not yet complete.
Open questions
Although the molecular basis for the involvement of HLA-
DQ in CD is now well established, a number of issues
remain unclear.
Fig. 4 Threshold model for CD
development. As HLA-DQ2.5
homozygous individuals can
present more gluten peptides on
their APC than HLA-DQ2.5
heterozygous individuals, HLA-
DQ2.5 homozygotes have a
higher risk of CD development a
priori. In steady state conditions,
presentation of native gluten
peptides is unlikely to induce
disease. This steady state can be
breached by frequent viral
infections and low-grade T cell
responses to native gluten pep-
tides that lead to release of TG2
upon tissue damage. TG2 activ-
ity will expand the presentable
gluten peptide repertoire exten-
sively, thereby increasing the
risk to develop CD. The recently
uncovered non-HLA genes
associated with CD likely lower
the threshold to develop CD
Box 3 Direct effects of gluten
The role of gluten in the adaptive immune response in CD is well established. In addition, a direct (innate) effect of gluten on the intestinal
mucosa has been suggested. One of the first indications for the potential of gluten to elicit a response in the epithelium came from in vivo
challenges where administration of gliadin caused villous atrophy and increase of IELs within 2–3h after gluten ingestion (Ciclitira et al. 1984).
This effect was later attributed to the non-immunodominant peptide p31-49 from alpha-gliadin (Sturgess et al. 1994). In vitro studies with p31-
49 showed that epithelial alterations were independent of CD4
+ Tcell activation. Furthermore, p31-49 stimulated IL-15 production in the lamina
propria of cultured biopsies from CD patients (Maiuri et al. 2003). The fact that p31-49 could activate the local immune system implied that a
receptor for p31-49 should exist. A transcellular transport pathway was proposed where anti-gliadin IgA antibodies were able to bind p31-49.
This complex would then bind the transferrin receptor CD71 which would provide protected trafficking across the intestinal epithelium
(Matysiak-Budnik et al. 2008). However, this mechanism would not function in all CD patients, as a relatively large fraction of them is IgA-
deficient (McGowan et al. 2008).
We also assessed the hypothesis that a receptor for p31-49 is present on intestinal epithelial cells. Binding of p31-49 to intestinal epithelial cell
lines, however, could not be detected, neither directly nor by either UV-crosslinking or TG2-induced transamidation (Tjon et al. unpublished
data). In the absence of a receptor through which p31-43 could exert its activity, the molecular mechanism underlying the biological effects
observed with this peptide remains unclear.
Immunogenetics (2010) 62:641–651 647First, it is still controversial how immunogenic gluten
peptides from the intestinal lumen reach the lamina propria
where they can prime gluten-specific T cells. It has been
suggested that gluten peptides can be transported during
transient increased intestinal permeability during enteroviral
infections (Stene et al. 2006) or by IgA-mediated retro-
transcytosis (Matysiak-Budnik et al. 2008). Yet, this issue is
far from resolved.
Second, a direct effect of gluten on the intestinal mucosa
has been attributed to a peptide from α-gliadin, p31-49
(Box 3). It remains unclear, however, whether and how this
peptide would exert its activity and contribute to the disease
development (Box 3).
Third, TG2 is a crucial factor in expanding the
presentable gluten peptide repertoire. In steady state
conditions, TG2 is present in an inactive form intracellular
and on the cell surface. An intriguing question is, therefore,
how TG2 is activated and released in CD. We propose that
TG2 is released upon tissue damage induced by the initial
CD4
+ T cell response to native gluten peptides (Figs. 2
and 3). Alternatively, a recent study proposed a role for
TLR3 ligands released during enteroviral infections that,
upon ligation with TLR3, could result in TG2 activation
( S i e g e le ta l .2008). These two possibilities are not
mutually exclusive.
Fourth, in active CD, disrupted IL-15 regulation results
in massive overexpression of IL-15. It remains unclear what
causes this disruption. As on a gluten-free diet, the adaptive
CD4
+ T cell response and IL-15 expression both decrease
(Mention et al. 2003); it is possible that the adaptive CD4
+
T cell response has a direct effect on IL-15 expression
(Fig. 3). Alternatively, innate signals delivered through
TLRs may be responsible for elevated IL-15 levels.
Finally, the events leading from uncomplicated CD to
RCD II and subsequent lymphoma development are still
poorly understood. Lymphoma cells develop from the
aberrant IELs in RCD II. One view is that aberrant IELs
derive from mature TCR
+ IELs that have undergone
oligoclonal expansion and lost surface TCR-CD3 expres-
sion due to overstimulation (Cellier et al. 1998). Alterna-
tively, aberrant IELs could derive from a distinct population
of CD3
− CD7
+ precursor cells that can develop into T cells
and NK cells (Gunther et al. 2005). In favor of the first
hypothesis: although aberrant IELs lack surface TCR-CD3
expression, they do express CD3 intracellularly and display
TCR-γ-gene rearrangements (Malamut et al. 2009).
Furthermore, microarray analysis in one study on TCR-
CD3
+ IEL lines from CD patients revealed a significant
decrease in the transcript levels of TCRα- and TCRβ-
chains (Meresse et al. 2006), indicating that IELs may
lower TCR expression in CD. We found that aberrant IELs
not only express CD3ε intracellularly, but also have
intracellular expression of the CD3γ, CD3δ, and ζ-chains
(Tjon et al. 2008). In favor of the second hypothesis: the
TCR chains were not always present (Tjon et al. 2008), and
TCR rearrangements were often incomplete (Tjon et al.
unpublished data). Furthermore, the full complement of
CD3 chains and incomplete TCR rearrangements have also
been observed in NK cell precursors, and even mature NK
cells can carry partially rearranged TCRs. A recent study
indicated that extrathymic TCR-gene rearrangement is an
ongoing event in the human small intestine throughout life
(Bas et al. 2009). This raises the possibility that aberrant
IELs derive from cells in an early stage of extrathymic
lymphocyte development.
Concluding remarks
Life used to be simple: CD was a rare disease, diagnosed in
1 in 1,000 individuals. Patients were HLA-DQ2
+ of HLA-
DQ8
+ and could be treated effectively with a gluten-free
diet. That was about it.
Now we know that CD affects ~1% of the population in
Western Europe and the USA, most of which remain
undiagnosed. Although good insight has been gained on the
immunopathology of CD—inflammation in both lamina
propria and epithelium—it remains unclear what triggers the
development of CD and why not every patient is equally
affected. In addition, with the recognition of RCD and RCD-
associatedlymphomathatdonot respond to a gluten-free diet,
CD has become a far more complicated disease.
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